Hospital groups have dismissed the Bucshon bill, with 340B Health’s Testoni calling it “the legislative version of a pharmaceutical industry wish list,” and arguing it would gut the program.
“The 340B Access Act is a nonstarter,” said Aimee Kuhlman, vice president of advocacy and grassroots at the AHA.
“It’s really hard to negotiate when one side just wants abandon their responsibilities,” she said, referring to drug companies.
Even some community health centers are divided on the Bucshon bill. Advocates for Community Health, which also represents community health centers, says it does not support the legislation and that it would make it difficult for health centers to continue to benefit from the program.